Anti-Mouse CD70 (Clone TAN1-7) – Purified in vivo GOLD™ Functional Grade

In Vivo Applications of Clone TAN1-7 in Mice

Clone TAN1-7 is a monoclonal antibody that specifically targets mouse CD70, a cytokine expressed on activated T cells, B cells, and dendritic cells. Its in vivo applications are primarily centered on modulating immune responses by disrupting the CD70-CD27 interaction, a pathway critically involved in lymphocyte activation and function.

Key Applications

• Blockade of CD70-CD27 Interaction: Clone TAN1-7 is used to block the interaction between CD70 (ligand) and CD27 (receptor), which is essential for costimulation and activation of both B and T cells in mice. This blockade can be leveraged to study the physiological and pathological roles of this pathway, including its influence on lymphocyte proliferation, cytotoxic T cell generation, and B cell activation.
• Investigation of Immune Regulation: By inhibiting CD70 signaling, researchers can explore how this pathway regulates immunoglobulin synthesis, natural killer cell cytotoxicity, and the activation of various lymphocyte subsets. This is particularly useful in models of autoimmunity, transplantation, and chronic inflammation.
• Oncology Research: Some evidence suggests that CD70 signaling can enhance the survivability of tumor cells and T cells, making TAN1-7 a tool for studying tumor immunology and evaluating potential immunotherapeutic strategies.
• Models of Immune-Mediated Diseases: The antibody can be used to dampen immune responses in experimental models where CD70-CD27 signaling exacerbates disease, such as certain autoimmune disorders or graft-versus-host disease (GVHD).
• Functional Studies of CD70-Expressing Cells: Because CD70 is expressed on activated but not resting lymphocytes, TAN1-7 can be used to selectively target and modulate the function of recently activated immune cells in vivo, providing insights into the dynamics of immune activation and memory.

Technical Details

• Specificity: TAN1-7 recognizes a direct epitope on mouse CD70, ensuring targeted action without cross-reactivity to unrelated antigens.
• Functional Grade: The antibody is manufactured for in vivo use, with low endotoxin levels and high purity to minimize off-target effects and toxicity in mice.
• Formulation: Typically supplied in PBS, free of carrier proteins and preservatives, making it suitable for direct in vivo administration.

Summary Table

Conclusion

Clone TAN1-7 is a valuable tool in mouse immunology research, enabling precise in vivo modulation of the CD70-CD27 pathway to dissect its role in immune activation, regulation, and disease models. Its applications span basic immunology, autoimmunity, transplantation, and cancer research, providing insights into both physiological and pathological immune processes.

The TAN1-7 antibody is most commonly used to detect or block CD70 in mouse models, and is frequently paired with other immunological markers and antibodies relevant to immune cell phenotyping and costimulatory pathways. In studies and vendor recommendations, commonly used antibodies or proteins alongside TAN1-7 (anti-CD70) include:

• CD27: As CD70 is the ligand for CD27, anti-CD27 antibodies are regularly used to study the CD70–CD27 interaction or to block its signaling in experiments investigating T and B cell activation.
• CD3, CD4, CD8: These T cell markers help delineate T cell subsets and their activation status; anti-CD3 for total T cells, anti-CD4 for helper T cells, and anti-CD8 for cytotoxic T cells.
• CD19 or B220: These B cell markers are often used for identifying B cells in tissues where CD70 expression is analyzed.
• CD11c: A dendritic cell marker, commonly used when studying CD70 expression on dendritic cells.
• Activation markers (such as CD69 or CD25): Utilized to monitor lymphocyte activation, often in combination with CD70 blockade or stimulation.
• Isotype controls: Used to rule out non-specific binding effects in flow cytometry and immunology assays.
• Functional antibodies for costimulatory molecules: Depending on study design, antibodies targeting other costimulatory molecules (e.g., anti-CD80, anti-CD86, anti-PD-1, anti-CTLA-4) may be included to dissect costimulatory or coinhibitory pathways.

These combinations are typical in experiments examining T cell and B cell activation, dendritic cell biology, immunoregulation, and in vivo immune responses.

Context and Literature Use:
According to product listings and reviews of the TAN1-7 clone, its blocking of CD70–CD27 interactions is a major application, making anti-CD27 a particularly common partner antibody for mechanistic studies. Studies addressing immune checkpoint biology or costimulatory signaling often use multiplex panels including CD70, CD27, and markers of immune cell identity and activation.

Summary Table: Common Markers/Antibodies Used with TAN1-7 (anti-CD70)| Target Marker | Application Context ||------------------|------------------------------------------------------|| CD27 | Ligand-receptor assays, costimulation studies || CD3 | T cell identification || CD4, CD8 | T cell subset characterization || CD19, B220 | B cell identification || CD11c | Dendritic cell studies || CD69, CD25 | Lymphocyte activation assays || PD-1, CTLA-4 | Coinhibitory pathway studies (immune checkpoint) || Isotype control antibodies | Specificity controls |

When designing panels that include TAN1-7, these markers provide context for immune cell type, activation state, and allow mechanistic dissection of CD70’s role in adaptive immune responses.

The key findings from scientific literature citing clone TAN1-7 focus on its specificity and utility as an antibody targeting mouse CD70, a molecule implicated in immune cell activation and potential therapeutic targeting:

• Clone TAN1-7 is a monoclonal antibody that recognizes a direct epitope on mouse CD70 and is capable of blocking the CD70-CD27 interaction crucial for B and T cell activation.
• CD70 serves as the ligand for the T cell costimulatory receptor CD27. Expression of CD70 is found on activated T cells, B cells, and dendritic cells.
• The CD70-CD27 axis plays important roles in:
  • Promoting activation, differentiation, and survival of both CD4 and CD8 T cells.
  • Enhancing B cell activation and antibody production.
  • Promoting natural killer (NK) cell survival and function.
• Pathological significance: Elevated CD70 expression is found in several cancers (hematological and solid tumors); it is associated with tumor cell proliferation, survival, and regulatory T cell (Treg) expansion, underscoring its relevance as a potential therapeutic target. Increased CD70 levels also play a role in autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus.
• The antibody has broad laboratory utility, being used in ELISA, flow cytometry, immunofluorescence, and in vivo experiments.
• Peer citations, such as van Lier et al., 1997, highlight foundational evidence on CD70 biology using TAN1-7 to dissect immune costimulation and regulatory mechanisms.

No evidence was found that clone TAN1-7 is used outside CD70 research, nor in areas such as genetic engineering or non-immunological pathways, from the provided literature. If a different "clone TAN1-7" or unrelated context was intended, please clarify.

Based on the available search results, there is insufficient specific information about how dosing regimens of clone TAN1-7 vary across different mouse models. The search results acknowledge that "literature mainly discusses TAN1/Tan1 genes" rather than providing detailed dosing protocols for the TAN1-7 antibody clone.

Clone TAN1-7 is an anti-mouse CD70 monoclonal antibody (IgG2a isotype) that targets CD70 (also known as CD27 ligand or TNFSF7). While this antibody is available in purified form for in vivo functional studies, the search results do not contain published data on specific dosing regimens, dose ranges, or how these parameters might differ across various mouse disease models.

To determine appropriate dosing regimens for clone TAN1-7 in specific mouse models, researchers would typically need to consult:

• Primary literature specifically examining this clone in relevant disease models
• Manufacturer protocols or technical bulletins
• General guidelines for antibody dosing in mice, which can vary widely depending on the experimental endpoint, mouse strain, disease model, and route of administration

The lack of readily available dosing information in the literature suggests that clone TAN1-7 may require empirical dose optimization for each specific experimental application and mouse model system.